Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3610-3617

  Maertens, Johan ^a   Cornely, Oliver A ^b   Ullmann, Andrew J ^c   Heinz, Werner J ^d   Krishna, Gopal ^e,f   Patino, Hernando ^e,f   Caceres, Maria ^e   Kartsonis, Nicholas ^e   Waskin, Hetty ^e   Robertson, Michael N ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Cubist Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POSACONAZOLE; ANTIFUNGAL AGENT; SOLUTION AND SOLUBILITY; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMORRHOID; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; AGED; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MYCOSIS; SOLUTION AND SOLUBILITY;

ADULT; AGED; ANTIFUNGAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; PHARMACEUTICAL SOLUTIONS; TRIAZOLES;

EID: 84903180158     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02686-13     Document Type: Article

References (25)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094. (Pubitemid 46148777)
2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10. 1056/NEJMoa061098. (Pubitemid 46148776)
3. Keating GM. 2005. Posaconazole. Drugs 65:1553-1567. http://dx.doi.org/10. 2165/00003495-200565110-00007. (Pubitemid 41124308)
4. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086/508774. (Pubitemid 44968977)
5. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. 2006. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403. http://dx.doi.org/10.1086/503425.
6. Noxafil. 2012. Noxafil (posaconazole) oral suspension; prescribing information. Merck & Co. Inc., Whitehouse Station, NJ.
7. Merck Sharp & Dohme Limited. 2012. Noxafil (posaconazole) oral suspension: summary of product characteristics. Merck Sharp & Dohme Limited, Hertfordshire, United Kingdom.
8. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222. http://dx.doi.org/10.1046/ j.1365-2125.2003.01977.x. (Pubitemid 38223535)
9. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
10. Krishna G, Ma L, Martinho M, O'Mara E. 2012. A single dose phase I study to evaluate the pharmacokinetics of posaconazole new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196-4201. http://dx.doi.org/10.1128/AAC.00222-12.
11. Pille S, Bohmer D. 1998. Options for artificial nutrition of cancer patients. Strahlenther. Onkol. 174:52-55. (Pubitemid 28506594)
12. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50:1881-1883. http://dx.doi.org/10. 1128/AAC.50.5.1881-1883.2006.
13. Pfizer Inc. 2011. VFEND IV (voriconazole) for injection, VFEND tablets (voriconazole), VFEND (voriconazole) for oral suspension: prescribing information. Pfizer, Inc., New York, NY.
14. Janssen-Cilag Limited. 2013. Sporanox IV (itraconazole) 10 mg/ml concentrate and solvent for solution for infusion: summary of product characteristics. Janssen-Cilag Limited, Buckinghamshire, United Kingdom.
15. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010.64.
16. van Iersel T, Nassander U, Kersemaekers WM, Xuan F, Caceres M, Waskin H. 2013. Pharmacokinetics (PK) and safety study of posaconazole (POS) i.v. solution via peripheral administration in healthy subjects. Poster. 53rd Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC); American Society for Microbiology, Denver, CO, 10 to 13 September 2013.
17. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236. http://dx.doi.org/10.1016/j.jpba.2006.06. 011. (Pubitemid 44856187)
18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821. http://dx.doi.org/10.1086/588660.
19. Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC. 2012. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob. Agents Chemother. 56:2652-2658. http://dx.doi.org/10. 1128/AAC.05937-11.
20. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627. (Pubitemid 350234311)
21. Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship of posaconazole used for prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352. http://dx.doi.org/10.1038/clpt. 2010.261.
22. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.00802-12.
23. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx.doi.org/10. 1128/AAC.05900-11.
24. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015. http://dx.doi.org/10.1128/AAC.00163-06. (Pubitemid 43807519)
25. Krishna G, Tarif MA, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.